Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Expression of human ficolin-2 in hepatocytes confers resistance to infection by diverse hepatotropic viruses.

Jalal PJ, Urbanowicz RA, Horncastle E, Pathak M, Goddard C, Saeed A, Mason CP, Ball JK, Irving WL, McClure CP, King BJ, Tarr AW.

J Med Microbiol. 2019 Apr;68(4):642-648. doi: 10.1099/jmm.0.000935. Epub 2019 Feb 12.

PMID:
30747617
2.

Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells.

Urbanowicz RA, Wang R, Schiel JE, Keck ZY, Kerzic MC, Lau P, Rangarajan S, Garagusi KJ, Tan L, Guest JD, Ball JK, Pierce BG, Mariuzza RA, Foung SKH, Fuerst TR.

J Virol. 2019 Mar 21;93(7). pii: e01403-18. doi: 10.1128/JVI.01403-18. Print 2019 Apr 1.

3.

Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp).

Bailey JR, Urbanowicz RA, Ball JK, Law M, Foung SKH.

Methods Mol Biol. 2019;1911:441-450. doi: 10.1007/978-1-4939-8976-8_30.

4.

Cloning and Analysis of Authentic Patient-Derived HCV E1/E2 Glycoproteins.

Urbanowicz RA, Ball JK, Tarr AW.

Methods Mol Biol. 2019;1911:275-294. doi: 10.1007/978-1-4939-8976-8_19.

PMID:
30593633
5.

Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies.

Tarr AW, Backx M, Hamed MR, Urbanowicz RA, McClure CP, Brown RJP, Ball JK.

Antiviral Res. 2018 Dec;160:25-37. doi: 10.1016/j.antiviral.2018.09.005. Epub 2018 Sep 11.

PMID:
30217650
6.

Enhanced nanoparticle uptake into virus infected cells: Could nanoparticles be useful in antiviral therapy?

Abo-Zeid Y, Urbanowicz RA, Thomson BJ, Irving WL, Tarr AW, Garnett MC.

Int J Pharm. 2018 Aug 25;547(1-2):572-581. doi: 10.1016/j.ijpharm.2018.06.027. Epub 2018 Jun 13.

PMID:
29908332
7.

A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.

Desombere I, Mesalam AA, Urbanowicz RA, Van Houtte F, Verhoye L, Keck ZY, Farhoudi A, Vercauteren K, Weening KE, Baumert TF, Patel AH, Foung SKH, Ball J, Leroux-Roels G, Meuleman P.

Antiviral Res. 2017 Dec;148:53-64. doi: 10.1016/j.antiviral.2017.10.015. Epub 2017 Oct 23.

8.

Human Adaptation of Ebola Virus during the West African Outbreak.

Urbanowicz RA, McClure CP, Sakuntabhai A, Sall AA, Kobinger G, Müller MA, Holmes EC, Rey FA, Simon-Loriere E, Ball JK.

Cell. 2016 Nov 3;167(4):1079-1087.e5. doi: 10.1016/j.cell.2016.10.013.

9.

Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay.

Urbanowicz RA, McClure CP, King B, Mason CP, Ball JK, Tarr AW.

J Gen Virol. 2016 Sep;97(9):2265-2279. doi: 10.1099/jgv.0.000537. Epub 2016 Jul 6.

10.

Flexible and rapid construction of viral chimeras applied to hepatitis C virus.

McClure CP, Urbanowicz RA, King BJ, Cano-Crespo S, Tarr AW, Ball JK.

J Gen Virol. 2016 Sep;97(9):2187-2193. doi: 10.1099/jgv.0.000530. Epub 2016 Jun 21.

11.

Hepatitis C virus quasispecies and pseudotype analysis from acute infection to chronicity in HIV-1 co-infected individuals.

Ferns RB, Tarr AW, Hue S, Urbanowicz RA, McClure CP, Gilson R, Ball JK, Nastouli E, Garson JA, Pillay D.

Virology. 2016 May;492:213-24. doi: 10.1016/j.virol.2016.02.003. Epub 2016 Mar 21.

12.

A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.

Urbanowicz RA, McClure CP, Brown RJ, Tsoleridis T, Persson MA, Krey T, Irving WL, Ball JK, Tarr AW.

J Virol. 2015 Dec 23;90(7):3288-301. doi: 10.1128/JVI.02700-15.

13.

An ancestral host defence peptide within human β-defensin 3 recapitulates the antibacterial and antiviral activity of the full-length molecule.

Nigro E, Colavita I, Sarnataro D, Scudiero O, Zambrano G, Granata V, Daniele A, Carotenuto A, Galdiero S, Folliero V, Galdiero M, Urbanowicz RA, Ball JK, Salvatore F, Pessi A.

Sci Rep. 2015 Dec 21;5:18450. doi: 10.1038/srep18450.

14.

Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.

Paciello R, Urbanowicz RA, Riccio G, Sasso E, McClure CP, Zambrano N, Ball JK, Cortese R, Nicosia A, De Lorenzo C.

J Gen Virol. 2016 Jan;97(1):82-94. doi: 10.1099/jgv.0.000330. Epub 2015 Oct 29.

15.

Cholesterol conjugation potentiates the antiviral activity of an HIV immunoadhesin.

Urbanowicz RA, Lacek K, Lahm A, Bienkowska-Szewczyk K, Ball JK, Nicosia A, Cortese R, Pessi A.

J Pept Sci. 2015 Sep;21(9):743-9. doi: 10.1002/psc.2802.

PMID:
26292842
16.

Dramatic potentiation of the antiviral activity of HIV antibodies by cholesterol conjugation.

Lacek K, Urbanowicz RA, Troise F, De Lorenzo C, Severino V, Di Maro A, Tarr AW, Ferrara F, Ploss A, Temperton N, Ball JK, Nicosia A, Cortese R, Pessi A.

J Biol Chem. 2014 Dec 12;289(50):35015-28. doi: 10.1074/jbc.M114.591826. Epub 2014 Oct 23.

17.

Recombinant human L-ficolin directly neutralizes hepatitis C virus entry.

Hamed MR, Brown RJ, Zothner C, Urbanowicz RA, Mason CP, Krarup A, McClure CP, Irving WL, Ball JK, Harris M, Hickling TP, Tarr AW.

J Innate Immun. 2014;6(5):676-84. doi: 10.1159/000362209. Epub 2014 May 15.

18.

Analysis of serine codon conservation reveals diverse phenotypic constraints on hepatitis C virus glycoprotein evolution.

Brown RJ, Koutsoudakis G, Urbanowicz RA, Mirza D, Ginkel C, Riebesehl N, Calland N, Albecka A, Price L, Hudson N, Descamps V, Backx M, McClure CP, Duverlie G, Pecheur EI, Dubuisson J, Perez-del-Pulgar S, Forns X, Steinmann E, Tarr AW, Pietschmann T, Ball JK.

J Virol. 2014 Jan;88(1):667-78. doi: 10.1128/JVI.01745-13. Epub 2013 Oct 30.

19.

An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission.

Tarr AW, Lafaye P, Meredith L, Damier-Piolle L, Urbanowicz RA, Meola A, Jestin JL, Brown RJ, McKeating JA, Rey FA, Ball JK, Krey T.

Hepatology. 2013 Sep;58(3):932-9. doi: 10.1002/hep.26430. Epub 2013 Jul 30.

PMID:
23553604
20.

Differential activation of killer cells in the circulation and the lung: a study of current smoking status and chronic obstructive pulmonary disease (COPD).

Wang J, Urbanowicz RA, Tighe PJ, Todd I, Corne JM, Fairclough LC.

PLoS One. 2013;8(3):e58556. doi: 10.1371/journal.pone.0058556. Epub 2013 Mar 11.

21.

The role of humoral innate immunity in hepatitis C virus infection.

Tarr AW, Urbanowicz RA, Ball JK.

Viruses. 2012 Jan;4(1):1-27. doi: 10.3390/v4010001. Epub 2012 Jan 5. Review.

22.

Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization.

Tarr AW, Urbanowicz RA, Jayaraj D, Brown RJ, McKeating JA, Irving WL, Ball JK.

J Virol. 2012 Mar;86(5):2739-49. doi: 10.1128/JVI.06492-11. Epub 2011 Dec 14.

23.

The role of neutralizing antibodies in hepatitis C virus infection.

Edwards VC, Tarr AW, Urbanowicz RA, Ball JK.

J Gen Virol. 2012 Jan;93(Pt 1):1-19. doi: 10.1099/vir.0.035956-0. Epub 2011 Nov 2. Review.

PMID:
22049091
24.

Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.

Tarr AW, Urbanowicz RA, Hamed MR, Albecka A, McClure CP, Brown RJ, Irving WL, Dubuisson J, Ball JK.

J Virol. 2011 May;85(9):4246-57. doi: 10.1128/JVI.01332-10. Epub 2011 Feb 16.

25.

Enhanced effector function of cytotoxic cells in the induced sputum of COPD patients.

Urbanowicz RA, Lamb JR, Todd I, Corne JM, Fairclough LC.

Respir Res. 2010 Jun 11;11:76. doi: 10.1186/1465-9921-11-76.

26.

Quantitative validation and comparison of multiplex cytokine kits.

Richens JL, Urbanowicz RA, Metcalf R, Corne J, O'Shea P, Fairclough L.

J Biomol Screen. 2010 Jun;15(5):562-8. doi: 10.1177/1087057110362099. Epub 2010 Feb 22.

PMID:
20176857
27.

Altered effector function of peripheral cytotoxic cells in COPD.

Urbanowicz RA, Lamb JR, Todd I, Corne JM, Fairclough LC.

Respir Res. 2009 Jun 22;10:53. doi: 10.1186/1465-9921-10-53.

28.

Systems biology coupled with label-free high-throughput detection as a novel approach for diagnosis of chronic obstructive pulmonary disease.

Richens JL, Urbanowicz RA, Lunt EA, Metcalf R, Corne J, Fairclough L, O'Shea P.

Respir Res. 2009 Apr 22;10:29. doi: 10.1186/1465-9921-10-29. Review.

29.

Killer cells in chronic obstructive pulmonary disease.

Fairclough L, Urbanowicz RA, Corne J, Lamb JR.

Clin Sci (Lond). 2008 Apr;114(8):533-41. doi: 10.1042/CS20070356. Review.

PMID:
18336369
30.

Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance.

McGinnity DF, Soars MG, Urbanowicz RA, Riley RJ.

Drug Metab Dispos. 2004 Nov;32(11):1247-53. Epub 2004 Jul 30.

PMID:
15286053

Supplemental Content

Loading ...
Support Center